DOCSLIB.ORG

FRACP Lecture Series AGENDA Investigations Haemophilia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FRACP Lecture Series AGENDA Investigations Haemophilia AGENDA FRACP Lecture Series z Lecture 1 – Bleeding disorders z Lecture 2 – Neutropenia and Thrombocytopenia z For each of these conditions the following should be addressed Nalini Pati z Clinical presentation z Initial investigations Consultant haematologist z Initial management z Potential complications z Therapeutic options z Indications for referral Investigations Haemophilia z Screening z PFA – 100 z What haemophilia was. investigations z Blood group z FBE z z Von Willebrand’s What haemophilia is. screen z APTT z What are the main problems with z PT / INR z Factor XIII haemophilia today. z Fibrinogen z TCT 1 2 Haemophilia Carrier Woman Healthy Man XH X X Y X X X X X Y X Y H H Carrier Girl Healthy Girl Haemophilic Boy Healthy Boy Haemophilia Haemophilia ––WorldWorld Healthy Woman Haemophilic Man Perspective z An estimated 250,000 patients in the world population. X X X Y H z Only about 50, 000 receive specific treatment. X X X X X Y X Y z Australia has approximately 1800 patients H H with haemophilia Carrier Girl Carrier Girl Healthy Boy Healthy Boy Haemophilia Management 2008 Haemophilia Prophylaxis z Clotting factor replacement is the cornerstone of z Prophylaxis treatment z Regular infusions of (recombinant) clotting z Recent (October 2004) Federal and State Government consensus to fund recombinant FVIII and FIX for all factor concentrate to prevent joint and muscle patients with haemophilia in Australia bleeds z Clotting factor needs to be given directly into the into veins z Majority of children begin prophylaxis after the first or second joint bleed z Factor replacement can be given for treatment AND prevention (prophylaxis) of bleeds z The use of early prophylaxis has significantly reduced the complication of joint disease 3 FVIII and FIX Inhibitors z Most serious complication z FVIII or FIX proteins recognised as “foreign” z Stimulating immune response and formation of IgG z Occurs in 30% patients severe haemophilia A and 5% patients haemophilia B FVIII and FIX Inhibitors Haemophilia 2008 z Renders treatment and prophylaxis ineffective z Whilst inhibitors in haemophilia are still a major problem, the modern management z Limited treatment options and return to the of haemophilia prevents the traditional “natural history of haemophilia” complications of joint disease z Current treatment option to treat haemorrhage in z The availability of recombinant clotting patients with haemophilia (rFVIIa – NovoVII) factor concentrate limits the risk of particularly expensive transfusion transmitted viral disease Structure of Haemophilia Care in Australia z National Blood Authority provides funds for clotting factor concentrate z 30% state / 70% federal z Management run through haemophilia Diagnos is TitiTransition individual treatment centers 4 12 – 24 months of age • Onset of joint bleeds Diagnos is TitiTransition Diagnos is TitiTransition < 12 months of age • Addressing psychological impact of X linked recessive disorder 2 years – 5 years • Commencement of home based therapy Diagnos is TitiTransition Diagnos is TitiTransition > 5 years • Are boys with hemophilia as active, fit and happy as their peers? Modern Morbidities of Haemophilia Virchow’s Triad in Haemophilia z Impact on family functioning Vessel Wall z Support of home based therapy z Complications of central venous lines z Activity levels z Bone density z Maintenance of Healthy Weight Thrombosis z Maximizing Education Potential Blood Blood composition Flow 5 Activity Levels Bone Density z In the modern era of haemophilia z Importance of musculomusculo--skeletalskeletal integrity management, are boys with haemophilia (including maintaining adequate bone as active as their peers? density) z What are the implications of reduced z Patients with haemophilia may be at risk of levels of activity in boys with haemophilia? developing reduced bone density z Bone density z Reduced weight bearing exercise z Maintenance of Healthy Weight z Prolonged periods of immobility Figure 1 Bone mineral density (BMD) of lumbar spine and total body and bone mineral apparent density (BMAD) of lumbar spine plotted by age in boys and girls. The bold line represents the fitted line, the thin lines represent {+/-}2 SD. Bone Density van der Sluis, I M et al. Arch Dis Child 2002;87:341-347 Bone Density Maintenance of Healthy Weight z Obesity is a major public health problem z Greater access to calorie dense foods z Reduced activity (greater access to sedentary pastimes) 6 Risk Factors Maintenance of Healthy Weight z Are boys with haemophilia more prone to becoming overweight? z Predisposed to becoming overweight on the basis of reduced physical activity Maintenance of Healthy Weight in Changing Morbidities of Haemophilia Haemophilia z Implications for patients with haemophilia and obesity significant z As a result of the major advances in haemophilia care there is the opportunity z Complicated venous access to focus on a different range of co- z Increased clotting factor usage morbidities z Exacerbation of established joint disease Von Willebrand disease z Type 1 z 80% z Mild to moderate quantitative reductions in VWF von Willebrand’s disease levels z T2Type 2 z 20% z Qualitative defects z Type 3 z Virtual deficiency of VWF 7 Type 1 VWD Type 1 VWD z Prospective studies have suggested 1% of z VWD is an inherited disease that causes population affected bleeding and type 1 VWD is a quantitative deficiency of VWF. z Ter tiary re ferra l cen tres 1 in 10, 000 Type 1 VWD (ISTH) Von Willebrand Disease in the Neonate z All of the following criteria must be met z A significant history of mucocutaneous bleeding z VWF:Ag and CBA increased in the z Laboratory tests compatible with type I VWD neonatal population z Either a positive family history or an appropriate genetic mutation z Reach adult levels by 6 months of age Royal Children’s Hospital Royal Children’s Hospital Type VWD 1 VWD z Vast majority of patients have Type 1 z Patients referred from surgical services, VWD adolescent gynaecology and external ggpeneral practitioners z Type 2 VWD z ? 4 patients z Routine investigations z Type 3 VWD z Family testing performed as routine z 1 patient z DDAVP challenge performed as routine 8 DDAVP challenge Management of VWD z Relative contraindication in children less than 2 z Non transfusional therapies years of age z DDAVP z Thirty minute infusion of 0.3 mcg / kg (maximum z Sustain increase in FVIII / VWF 8 – 10 hours 20 mcg) z Given 12 – 24 hourly depending on documented response z VWF: Ag a t 30 m inu tes, 1 hour an d 4 hours z Tachyphylaxis after 4 doses z Restriction of fluid input over 12 hours following z Antifibrinolytics infusion z Transfusional therapies z One patient (10 months of age) developed seizures z BIOSTATE (AHF) secondary to hyponatramia following treatment with DDAVP Biostate Thrombocytopenia z Plasma derived FVIII / VWF z Inherited z Ratio of FVIII : VWF of 2:3 (product insert suggests Biostate ratio of 1:2) z Acquired (ITP) z 20 000 units on stock at all times at RCH Case Case z 3 week old male infant presenting with z Family history marked thrombocytopenia in the setting of z No significant history of bleeding, known possible vascular tumour of lower limb platelet disorders z Youngest of five children z Previous six miscarriages z Antenatal history z Largely unremarkable z Mother on aspirin for recurrent miscarriages z Consanguineous parents 9 Case z Presenting history z Presented at birth with large, fleshy vascular(?) lesion affecting the lower limb z Referred to paediatrician z Possible kaposiform haemangioendothelioma (KHE) z Treated with corticosteroids z Referred to haematology due to persistent thrombocytopenia Case z Initial investigations z Slightly anaemic, neutropenic and markedly thrombocytopenic z No evidence of coagulation activation z Ultrasound showed lesion in right cerebral hemisphere, confirmed on MRI as bleed (antenatal) z Managed with platelet transfusion with good response 10 Case Congenital Thrombocytopenia: “Tools” available for assessment z Progress z Platelet count & sizing z Reticulated platelets z Persistent marked thrombocytopenia despite involution of vascular lesion z Electron microscopy z Bone marrow aspiration and z Repeated bone marrow examination showing immunohistochemistry normocellular bone marrow but (?) decreasing megakaryocytes (confirmed on z Flow cytometry for platelet glycoproteins immunohistochemistry CD61) z Assessment of platelet function z PFA 100 z Patient “well” and not bleeding z Aggregometry z Molecular markers Platelet counting and sizing Platelet Counting & Sizing (Coulter principle) z Platelet count is not directly measured – derived RBCs from platelet histogram z Any particle sized between 2 to 20 fl is counted as a + - platelet z Any particle sized outside of 2 to 20 fl is not counted as a platelet PLT Cross section of Oscilloscope screen RBC aperture (60x50 micron) 11 Reticulated Platelets z “Immature platelets” z Larger mean platelet volume with higher RNA content z Flow cytometric method using the membrane permeable flurochrome thiazole orange to stain RNA z Sensitivity improved by using gating techniques incorporating CD61 z Reported as a percentage (lack of widely accepted standardization of normal values) Reticulated Platelets Bone Marrow Aspiration z May have a role in the distinguishing z Performed under general anaesthetic patients with ITP / consumptive states z Limited morbidity from those with decreased platelet production z Provides quantitative information with lim ite d qua lita tive in forma tion (corre la tion of
Load more

Recommended publications
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
    [Show full text]
  • Protein C and S Deficiency in Deep Vein Thrombosis Patients Referred to Iranian Blood Transfusion Organization, Kermanshah
    Protein C and S Deficiency in Deep Vein Thrombosis Patients Referred to Iranian Blood Transfusion Organization, Kermanshah Mehrdad Payandeh, 1 Mohammad Erfan Zare, 1, 2 Atefeh Nasir Kansestani, 1, 2 Kamran Ma nsouri, 1, 3 Zohreh Rahimi, 1, 4 Amir Hossein Hashemian, 5 Ebrahim Soltanian, 6 Hoshang Yousefi, 6 1Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran 2Student Research Committee, Kermanshah University of Medical Scien ces, Kermanshah, Iran 3Department of Molecular Medicine, School of advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran 4Department of Biochemistry, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Ir an 5Department of Biostatistics, Faculty of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran 6Research Center of Iranian Blood Transfusion Organization, Kermanshah, Iran Corresponding Author : Mohammad Erfan Zare, BSC student of M edical Lab Sciences. Medical Biology Research Center, P.O.Box: 1568, Sorkheh Lizheh, Kermanshah University of Medical Sciences, Kermanshah, Iran. E-mail : [email protected] Tel: +98 831 4276473 Fax: +98 831 4276471 Abstract Introduction: Normal homeostas is system has several inhibitor mechanisms in front of the amplifier’s natural clotting enzyme to prevent fibrin clots in the vessels. The main inhibitors of coagulation pathway are antithrombin (AT), protein C and protein S. Patients with hereditary defic iency of coagulation inhibitors are susceptible to venous thromboembolism (VTE). One of the major clinical manifestations of VTE is deep vein thrombosis (DVT). The present study has investigated the frequency of protein C and S deficiency among DVT patients that by using of these results and results from our previous study; we determined the most important hereditary risk factors for DVT in the Kermanshah Province of Iran with the Kurdish ethnic background.
    [Show full text]
  • Duchenne Muscular Dystrophy in a Female Patient with a Karyotype of 46,X,I(X)(Q10)
    Tohoku J. Exp. Med., 2010, 222, 149-153Karyotype Analysis of a Female Patient with DMD 149 Duchenne Muscular Dystrophy in a Female Patient with a Karyotype of 46,X,i(X)(q10) Zhanhui Ou,1 Shaoying Li,1 Qing Li,1 Xiaolin Chen,1 Weiqiang Liu1 and Xiaofang Sun1 1Institute of Gynecology and Obstetrics, The Third Affiliated Hospital of Guangzhou Medical College, Duobao Road, Guangzhou, China Duchenne muscular dystrophy (DMD) is a severe recessive X-linked form of muscular dystrophy caused by mutations in the dystrophin gene and it affects males predominantly. Here we report a 4-year-old girl with DMD from a healthy family, in which her parents and sister have no DMD genotype. A PCR-based method of multiple ligation-dependent probe amplification (MLPA) analysis showed the deletion of exons 46 and 47 in the dystrophin gene, which led to loss of dystrophin function. No obvious phenotype of Turner syndrome was observed in this patient and cytogenetic analysis revealed that her karyotype is 46,X,i(X)(q10). In conclusion, we describe the first female patient with DMD who carries a de novo mutation of the dystrophin gene in one chromosome and isochromosome Xq, i(Xq), in another chromosome. Keywords: Duchenne Muscular Dystrophy; de novo mutation; isochromosome Xq; karyotype; Turner syndrome Tohoku J. Exp. Med., 2010, 222 (2), 149-153. © 2010 Tohoku University Medical Press Duchenne muscular dystrophy (DMD) is a severe an uneventful pregnancy. At birth, her growth parameters recessive X-linked form of muscular dystrophy which is were normal. Her motor development was delayed: she characterized by rapid progression of muscle degeneration, could sit at 10 months and walk at 15 months, but fell down eventually leading to loss of ambulation and death.
    [Show full text]
  • Haematology: Non-Malignant
    Haematology: Non-Malignant Mr En Lin Goh, BSc (Hons), MBBS (Dist.), MRCS 25th February 2021 Introduction • ICSM Class of 2018 • Distinction in Clinical Sciences • Pathology = 94% • Wallace Prize for Pathology • Jasmine Anadarajah Prize for Immunology • Abrahams Prize for Histopathology Content 1. Anaemia 2. Haemoglobinopathies 3. Haemostasis and thrombosis 4. Obstetric haematology 5. Transfusion medicine Anaemia Background • Hb <135 g/L in males and <115 g/L in females • Causes: decreased production, increased destruction, dilution • Classified based on MCV: microcytic (<80 fL), normocytic (80-100 fL), macrocytic (>100 fL) • Arise from disease processes affecting synthesis of haem, globin or porphyrin Microcytic anaemia work-up • Key differentials • Iron deficiency anaemia • Thalassaemia • Sideroblastic anaemia • Key investigations • Peripheral blood smear • Iron studies Iron deficiency anaemia • Commonest cause is blood loss • Key features • Peripheral blood smear – pencil cells • Iron studies – ↓iron, ↓ferritin, ↑transferrin, ↑TIBC • FBC – reactive thrombocytosis • Management – investigate underlying cause, iron supplementation Thalassaemia • α-thalassaemia, β-thalassaemia, thalassaemia trait • Key features • Peripheral blood smear – basophilic stippling, target cells • Iron studies – all normal • Management – iron supplementation, regular transfusions, iron chelation Sideroblastic anaemia • Congenital or acquired • Key features • Peripheral blood smear – basophilic stippling • Iron studies – ↑iron, ↑ferritin, ↓transferrin, ↓TIBC • Bone
    [Show full text]
  • 5.1.1 OCR Exambuilder
    1. Thirty-three human blood group systems are known to exist. Two of these are the ABO blood group system and the Hh blood group system. Explain why a person whose blood group is AB expresses both A and B antigens on the surface of their red blood cells. [2] © OCR 2019. 1 of 42 PhysicsAndMathsTutor.com 2. Some varieties of maize plants have smooth kernels (seeds), whereas others have wrinkled kernels. This is a genetic trait. Varieties with smooth kernels are rich in starch and useful for making flour. A farmer has been given some smooth seeds all of the same unknown genotype. The farmer carries out a cross- breeding experiment using these seeds and some known to be heterozygous for this trait. The results are shown in Table 4.1. F1 phenotype Observed results Expected results Smooth 547 Wrinkled 185 Total 732 Table 4.1 The χ2 statistic is calculated in the following way: (i) Calculate the value of χ2 for the above data. Show your working. Answer _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ [2] (ii) Table 4.2 shows a critical values table. Degrees of freedom probability, p 0.90 0.50 0.10 0.05 1 0.016 0.455 2.71 3.84 2 0.211 1.386 4.61 5.99 3 0.584 2.366 6.25 7.81 4 1.064 3.357 7.78 9.49 Table 4.2 Using your calculated value of χ2 and Table 4.2 what conclusions should you make about the significance of © OCR 2019.
    [Show full text]
  • Understanding Haemophilia
    Understanding haemophilia Understanding haemophilia Contents Introduction 3 Haemophilia and your child 4 What is haemophilia? 5 What causes haemophilia? 5 Can females have haemophilia? 6 Carriers 8 Who is affected by haemophilia? 9 How severe is haemophilia? 9 Signs and symptoms of haemophilia 11 How is haemophilia diagnosed? 14 Diagnosis 14 Treatment 16 Port-a-cath 19 Managing joint bleeds with PRICE 19 Gene therapy 21 Possible complications of haemophilia 22 Inhibitors 22 Joint damage 22 Medical and dental treatment 23 Surgery Circumcision Dental care Medicines Vaccinations Bleeding disorder card Living with haemophilia 26 Sport and exercise 27 School, college and work 28 Travel 29 Pregnancy and haemophilia 30 Glossary of terms 32 About The Haemophilia Society 33 2 Understanding haemophilia Introduction This booklet is about haemophilia A and B. It gives a general overview of haemophilia and information on diagnosing, treating and living with the condition that we hope will answer your main questions. It has been written for people directly affected by haemophilia and for anyone interested in learning about haemophilia. If you are a parent and your child has recently been diagnosed with haemophilia you may be feeling quite overwhelmed. Remember, you’re not alone and many families are facing the same concerns and issues. Please do get in touch – we have lots of support and information available as well as services for parents and children. You can find out more via our website or Facebook pages, by emailing [email protected] or calling us on 020 7939 0780. The outlook is now the best it has ever been for people with haemophilia in the UK.
    [Show full text]
  • Understanding Haemophilia CHAPTER 2
    Understanding haemophilia CHAPTER 2 KEY POINTS • Haemophilia is an inherited condition caused by a gene alteration. • There are two types of haemophilia – A and B. • Haemophilia can be mild, moderate or severe. • Haemophilia is most commonly diagnosed in boys. • If you are considering having more children, there is support available to help with your decision. Haemophilia is an inherited bleeding disorder where blood doesn’t clot properly. It is caused when blood does not produce enough of one of the essential clotting ingredients. These ‘ingredients’ are clotting factors — proteins in the blood that control bleeding. The missing ingredient that causes haemophilia is usually either factor VIII (8) or IX (9). Roman numerals are used when referring to clotting factors. CHAPTER 2 2.1 UNDERSTANDING HAEMOPHILIA Blood clotting and bleeding Understanding how bleeding starts and stops NormalNormal clotting clotting process process Clotting factor activity Source: Hemophilia in Pictures. © WFH 2005. http://www1.wfh.org/publications/files/pdf-1311.pdf Bleeding starts when a capillary (small blood vessel) is injured and blood leaks out. When this happens, the capillary tightens up to slow the bleeding and blood cells called platelets make a plug to patch the hole. For people without haemophilia, the many clotting factors in plasma (part of the blood) knit together to make a clot over the plug. This makes the plug stronger and stops the bleeding. Clotting factor VIII and factor IX are essential to making the blood clot. 2.2 CHAPTER 2 UNDERSTANDING HAEMOPHILIA ClottingClotting in in haemophilia haemophilia Clotting factor activity Source: Hemophilia in Pictures. © WFH 2005.
    [Show full text]
  • Terminology Resource File
    Terminology Resource File Version 2 July 2012 1 Terminology Resource File This resource file has been compiled and designed by the Northern Assistant Transfusion Practitioner group which was formed in 2008 and who later identified the need for such a file. This resource file is aimed at Assistant Transfusion Practitioners to help them understand the medical terminology and its relevance which they may encounter in the patient’s medical and nursing notes. The resource file will not include all medical complaints or illnesses but will incorporate those which will need to be considered and appreciated if a blood component was to be administered. The authors have taken great care to ensure that the information contained in this document is accurate and up to date. Authors: Jackie Cawthray Carron Fogg Julia Llewellyn Gillian McAnaney Lorna Panter Marsha Whittam Edited by: Denise Watson Document administrator: Janice Robertson ACKNOWLEDGMENTS We would like to acknowledge the following people for providing their valuable feedback on this first edition: Tony Davies Transfusion Liaison Practitioner Rose Gill Transfusion Practitioner Marie Green Transfusion Practitioner Tina Ivel Transfusion Practitioner Terry Perry Transfusion Specialist Janet Ryan Transfusion Practitioner Dr. Hazel Tinegate Consultant Haematologist Reviewed July 2012 Next review due July 2013 Version 2 July 2012 2 Contents Page no. Abbreviation list 6 Abdominal Aortic Aneurysm (AAA) 7 Acidosis 7 Activated Partial Thromboplastin Time (APTT) 7 Acquired Immune Deficiency Syndrome
    [Show full text]
  • Autosomal Recessive Disorders and X Linked Disorders in Malaysia
    Patricia Bowen Library & Knowledge Service Email: [email protected] Website: http://www.library.wmuh.nhs.uk/wp/library/ DISCLAIMER: Results of database and or Internet searches are subject to the limitations of both the database(s) searched, and by your search request. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the results. Date: 27 January 2020 Sources Searched: Medline, Embase. Autosomal Recessive Disorders and X Linked Disorders in Malaysia See full search strategy 1. International perspectives on the implementation of reproductive carrier screening. Author(s): Delatycki, Martin B; Alkuraya, Fowzan; Archibald, Alison; Castellani, Carlo; Cornel, Martina; Grody, Wayne W; Henneman, Lidewij; Ioannides, Adonis S; Kirk, Edwin; Laing, Nigel; Lucassen, Anneke; Massie, John; Schuurmans, Juliette; Thong, Meow-Keong; van Langen, Irene; Zlotogora, Joël Source: Prenatal diagnosis; Nov 2019 Publication Date: Nov 2019 Publication Type(s): Journal Article Review PubMedID: 31774570 Available at Prenatal diagnosis - from Wiley Online Library Abstract:Reproductive carrier screening started in some countries in the 1970s for hemoglobinopathies and Tay-Sachs disease. Cystic fibrosis carrier screening became possible in the late 1980s and with technical advances, screening of an ever increasing number of genes has become possible. The goal of carrier screening is to inform people about their risk of having children with autosomal recessive and X-linked recessive disorders, to allow for informed decision making about reproductive options. The consequence may be a decrease in the birth prevalence of these conditions, which has occurred in several countries for some conditions. Different programs target different groups (high school, premarital, couples before conception, couples attending fertility clinics, and pregnant women) as does the governance structure (public health initiative and user pays).
    [Show full text]
  • Haemophilia A
    Haemophilia A Information for families Great Ormond Street Hospital for Children NHS Foundation Trust 2 Haemophilia A (also known as Classic Haemophilia or Factor VIII deficiency) is the most well-known type of clotting disorder. A specific protein is missing from the blood so that injured blood vessels cannot heal in the usual way. This information sheet from Great Ormond Street Hospital (GOSH) explains the causes, symptoms and treatment of Haemophilia A and where to get help. What is a clotting disorder? A clotting (or coagulation) disorder is a factor) turned on in order. When all of the medical condition where a specific protein factors are turned on, the blood forms a is missing from the blood. clot which stops the injury site bleeding Blood is made up of different types of any further. cells (red blood cells, white blood cells and There are a number of coagulation factors platelets) all suspended in a straw-coloured circulating in the blood, lying in wait to be liquid called plasma. Platelets are the cells turned on when an injury occurs. If any one responsible for making blood clot. When of the factors is missing from the body, the a blood vessel is injured, platelets clump complicated chemical reaction described together to block the injury site. They also above will not happen as it should. This can start off a complicated chemical reaction lead to blood loss, which can be severe and to form a mesh made of a substance called life-threatening. Each coagulation factor fibrin. This complicated chemical reaction is given a number from I to XIII – they are always follows a strict pattern – with each always written as Roman numerals – and clotting protein (known as a coagulation the effects of the missing factor will vary.
    [Show full text]
  • Delivery of Treatment for Haemophilia
    WHO/HGN/WFH/ISTH/WG/02.6 ENGLISH ONLY Delivery of Treatment for Haemophilia Report of a Joint WHO/WFH/ISTH Meeting London, United Kingdom, 11 - 13 February 2002 Human Genetics Programme, 2002 Management of Noncommunicable Diseases World Health Organization Human Genetics Programme WHO/HGN/WFH/ISTH/WG/02.6 Management of Noncommunicable Diseases ENGLISH ONLY World Health Organization Delivery of Treatment for Haemophilia Report of a Joint WHO/WFH/ISTH Meeting London, United Kingdom, 11- 13 February 2002 Copyright ã WORLD HEALTH ORGANIZATION, 2002 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Gene Therapy: the Promise of a Permanent Cure
    INVITED COMMENTARY Gene Therapy: The Promise of a Permanent Cure Christopher D. Porada, Christopher Stem, Graça Almeida-Porada Gene therapy offers the possibility of a permanent cure for By providing a normal copy of the defective gene to the any of the more than 10,000 human diseases caused by a affected tissues, gene therapy would eliminate the problem defect in a single gene. Among these diseases, the hemo- of having to deliver the protein to the proper subcellular philias represent an ideal target, and studies in both animals locale, since the protein would be synthesized within the cell, and humans have provided evidence that a permanent cure utilizing the cell’s own translational and posttranslational for hemophilia is within reach. modification machinery. This would ensure that the protein arrives at the appropriate target site. In addition, although the gene defect is present within every cell of an affected ene therapy, which involves the transfer of a func- individual, in most cases transcription of a given gene and Gtional exogenous gene into the appropriate somatic synthesis of the resultant protein occurs in only selected cells of an organism, is a treatment that offers a precise cells within a limited number of organs. Therefore, only cells means of treating a number of inborn genetic diseases. that express the product of the gene in question would be Candidate diseases for treatment with gene therapy include affected by the genetic abnormality. This greatly simplifies the hemophilias; the hemoglobinopathies, such as sickle- the task of delivering the defective gene to the patient and cell disease and β-thalassemia; lysosomal storage diseases achieving therapeutic benefit, since the gene would only need and other diseases of metabolism, such as Gaucher disease, to be delivered to a limited number of sites within the body.
    [Show full text]